The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment
The DOI matches its Crossref record, with a small difference in title or year; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The chylomicronemia syndrome occurs when triglyceride levels are severely elevated (usually >16.95 mmol/L [1500 mg/dL]) and is characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis. It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed familial chylomicronemia syndrome (FCS); or familial partial lipodystrophy. Most chylomicronemia syndrome cases are the result of MFCS; FCS is very rare. In all these conditions, triglyceride-rich lipoproteins accumulate because of impaired plasma clearance. This review describes the 3 major causes of the chylomicronemia syndrome; their consequences; and the approaches to treatment, which differ considerably by group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multifactorial chylomicronemia syndrome is the most common of the 3 conditions that elevate triglycerides levels high enough to provoke the characteristic clinical features of excess chylomicronemia, which include lipemia retinalis, eruptive xanthomas, abdominal pain, and hyperlipidemic pancreatitis (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Clearance of triglycerides from plasma is saturable when plasma triglyceride levels exceed approximately 500 to 700 mg/dL and further input of chylomicrons and VLDL into plasma cannot readily be removed, leading to marked hypertriglyceridemia and chylomicronemia, even after an overnight fast (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Lipoprotein lipase-mediated lipolysis of newly secreted TRLs is a saturable process, and as secretion rates and plasma TG levels rise, lipolysis falls.14”
From Clinical review on triglycerides (2020) · cites this paper as [14]
In the citing paper
“However, pancreatitis risk is highest in rare patients with monogenic chylomicronaemia, in which chylomicrons are indeed the predominant species, with low to undetectable levels of remnants and downstream lipoproteins due to severely impaired lipolytic machinery.6,14,29,30”
From Clinical review on triglycerides (2020) · cites this paper as [14]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Prognostic signs and the role of operative management in acute pancreatitis.
Ranson, J. H. C., Rifkind, K., Roses, D. F., Fink, S. D., Eng, K., & Spencer, F. C. (1974) · PubMed · Cited by 1,347
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Research works printed but not linked: 3
- Fortson MR, 1995, Am J Gastroenterol, 90, 2134
- Ranson JH, 1974, Surg Gynecol Obstet, 139, 69
- Khan AS, 2010, JOP, 11, 545
Cited by
Items 101–128 of 128
Genetic testing in dyslipidaemia: An approach based on clinical experience
Berberich, A. J., & Hegele, R. A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101720 · Cited by 2
Olanzapine-induced multifactorial chylomicronaemia syndrome: a rare but important complication
Cooper, B., Blaker, K., & Greenfield, J. R. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0225 · Cited by 1
Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome
Berberich, A. J., & Hegele, R. A. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117528 · Cited by 1
Novel therapeutics in hypertriglyceridaemia and chylomicronaemia
García-Díaz, J. D. D. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.11.004
Severe hypertriglyceridemia (hyperchylomicronemia), an actual challenge in daily clinic
Roeck, Y. D., & Twickler, M. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13399
Nyrén, R. (2020) · DiVA at Umeå University (Umeå University)
Primär genetische Dyslipoproteinämien und Atheroskleroserisiko
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_3
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Síndrome de quilomicronemia: aspectos genéticos y revisión de la literatura
Ricardo Fuentes, U., & Rosa Pardo, V. (2022) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2022.68961 · Cited by 2
Lourenço, C. M., Corral, P., Santos, R. D., Nogueira, J. P., Mendivil, C. O., Santos, J. L., Pachajoa, H., Bañares, V. G., & Mattos-Velez, M. B. (2024) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1590/2326-4594-jiems-2023-0005
A Quick Dive into the General Medicine Floor with an Emphasis on Cardiology
Zhou, K. (2024) · Springer eBooks · doi:10.1007/978-1-0716-4039-5_4
Multifactorial chylomicronemia: Keys to detecting severe forms
Muñiz-Grijalvo, O., Echevarría, A. B., Corbo, M. J. A., & Diaz-Diaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100749
Montalvo, A. F., González‐Andrade, F., Molestina, M. J., Carranza, J., Maldonado, C., Battaglini, D., & Vélez-Páez, J. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061827
“The most affected gene is LPL, accounting for approximately 60–80% of FCS cases, although mutations have also been identified in other genes, such as APOC2, APOA5, GPIHBP1, and LMF1 [7].”
A case of familial hypertriglyceridemia associated with a novel heterozygous AGPAT2 mutation
AbuDujain, N. M., Alekrish, Y., Alyusuf, E. Y., Alsadhan, I., Albanyan, S., Almigbal, T. H., Ekhzaimy, A. A., & Al-Maatouq, M. A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003167
The Importance of Hypertriglyceridemia: Risk of Atherosclerosis and Available Treatments
Hegele, R. A. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.113
Severe Hypertriglyceridemia in the Hospitalized Patient
Mateo, R. C. I., & Ganda, O. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-86099-7_28 · Cited by 1
Bedi, A., Kermanshah, A., Bedi, S., & Kalaydjian, G. (2025) · Cureus · doi:10.7759/cureus.96610
“Familial hypertriglyceridemia Type V often exhibits TG levels in the 1,000-5,000 mg/dL range due to increased VLDL and chylomicron production, while Type I (familial chylomicronemia from LPL deficiency) typically presents with TG >2,000 mg/dL and may exceed 10,000 mg/dL [5,12].”
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046914
Berberich, A. J., Ouédraogo, A. M., Shariff, S. Z., Hegele, R. A., & Clemens, K. K. (2021) · Figshare · doi:10.6084/m9.figshare.16570289
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046917
Lu, T., Zhuge, F., Cai, W., Zhang, X., Lou, D., & Huang, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1764866
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
“Chylomicron particles contain >90% TG in their core, surrounded by various surface proteins including apo A-I, A-V, B-48, C-II, C-III, and E [4].”
Goiriz, B. M. F., Rojas, M. N. D. P., Centurión, J. N. M., Núñez, M. G. G., Rotela-Fisch, V., Goiburú-Chenú, M. B., Ortíz, B. D. M., & Caballero, A. B. A. (2026) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2026.e13142606
Stefanutti, C., Zeppa, G., Perrone, G., Labbadia, G., Galoppi, P., Demarco, V., Fornari, E., Bordugo, A., Santelia, C., Mancioppi, V., et al. (2026) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2026.101353
Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis
Masson, W. M., Lobo, M., MANSUR, M., Solís, C., & Nogueira, J. P. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03783-1
Eruptive Xanthoma: A Case of Extreme Hypertriglyceridemia
Xu, Z., Bi, L., Wang, Z., Sheng, Y., & Cui, Y. (2026) · Skin · doi:10.2738/skin.2026.0034
Kastelein, J. J. P., Skjæret, T., Jeannin, S., Besuyen, R., Fraser, D. A., & Maki, K. C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.016
Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“It results from genetic susceptibility combined with secondary drivers such as obesity, diabetes, alcohol intake, pregnancy, TG-raising medications, or dietary factors [ 35, 47, 48 ].”
Metadata
- Authors
- Chait, A., & Eckel, R. H.
- Affiliations
- University of Washington (US)
- University of Colorado Anschutz (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-07
- Volume
- 170
- Issue
- 9
- Pages
- 626-634
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2942839572
- Cited by
- 128
- References
- 94
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 25 · 2021: 12 · 2020: 27 · 2019: 4
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- chylomicronemia syndrome, hypertriglyceridemia, familial chylomicronemia syndrome, familial partial lipodystrophy, lipoprotein lipase deficiency, triglyceride-rich lipoproteins, lipoprotein clearance, eruptive xanthoma, lipemia retinalis, acute pancreatitis, treatment options
- MeSH terms
- Algorithms, Hypolipidemic Agents, Apolipoproteins, Cardiovascular Diseases, Chylomicrons, Humans, Lipoprotein Lipase, Hyperlipoproteinemia Type I, Mutation, Oligonucleotides, Pancreatitis, Risk Factors, Hypertriglyceridemia, Fatty Acids, Omega-3, Receptors, Lipoprotein, Genetic Predisposition to Disease, Angiopoietins, Lipodystrophy, Familial Partial, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.